Application of piceatannol in preparation of medicine for preventing and/or treating herpes simplex virus infection

A technology of herpes simplex virus and piceatanol, which is applied in the field of medicine, achieves good market application prospects and improves the effect of physical condition

Pending Publication Date: 2022-01-04
THE AFFILIATED HOSPITAL OF QINGDAO UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of picatanol on herpe...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of piceatannol in preparation of medicine for preventing and/or treating herpes simplex virus infection
  • Application of piceatannol in preparation of medicine for preventing and/or treating herpes simplex virus infection
  • Application of piceatannol in preparation of medicine for preventing and/or treating herpes simplex virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Piceatannol effect in vitro inhibition of herpes simplex virus: Example 1

[0032] 1. Experimental Methods

[0033] 1.1 Cytotoxicity test of piceatannol

[0034] Determination piceatannol cytotoxicity in three cell lines, the Vero, Hela, Hep-2 cells were seeded in 96-well plates, after 24 h, disposable suction original culture medium, serial dilutions of the piceatannol ( final concentration of 400 μM, 200 μM, 100 μM, 50 μM) was added a 96 well plate, three wells for each concentration, while with the control group. Cells were placed in 37 ℃, containing 5% CO 2 After the temperature in the cell culture incubator 24h, aspirated the drug, 4% paraformaldehyde fixed at room temperature 15 min, aspirated, 5% crystal violet staining rt 15 min, measured using a microplate reader A dry after washing 540nm value.

[0035] A cell viability test group = 540nm / A negative control group 540nm × 100%.

[0036] 1.2 cytopathic effect (CPE) inhibition test piceatannol detection of the viru...

Embodiment 2

[0053] Example 2: Mechanism piceatannol inhibition of HSV virus

[0054] 1. Experimental Methods

[0055] 1.1 plaque forming assay

[0056] Vero cells were seeded in 12-well plates to its covered with a monolayer. 1.2 following the experimental procedure in four different modes of administration Wedelia lactone were added (final concentration 10 μM), 24h after the supernatant was collected, while the virus is provided in the control group. The supernatant was diluted 10 charges -1 ~ 10 -3 Times, 37 [deg.] C cells adsorbed to 1 h, aspirated, the prepared overlay medium was added, After cooling solidification, inverted at 37 ℃ incubator. After the spots to which fixing stained for plaque counting.

[0057] 1.2 Western blot test

[0058] Vero cells were seeded in 6-well plates, cells covered monolayer, serial dilutions piceatannol after HSV-1 and HSV-2 in the pre-mixed 37 ℃ 1 h, added to 6-well plates, 37 ℃ 1 H, aspirated, and replaced with maintenance medium, and with the virus cont...

Embodiment 3

[0072] Example 3: Effect of piceatannol treat HSV infected mice

[0073] 1. Experimental Methods

[0074] 1.1 Experimental modeling

[0075]All mice used in this case are in line with the humanitarian treatment of the Chinese science and technology experiment (VGKFCZ-2006-398). Babl / C female mice using three weeks of age, weight 10 to 12 g, randomly divided into normal control group, virus control group, positive drug acyclovir group (10 mg / kg / day), white psol High dosing group (5 mg / kg / day), white pine fedol low dose group (2.5 mg / kg / day), a total of 5 groups. The mice were infected by dripping nose, and 50 μl of viruses were added to the nasal cavity of each mouse. The normal control group dropped with the amount of physiological saline.

[0076] 1.2 Administration method and clinical observation

[0077] After 4 h after viral infection, it was administered in the abdominal injection, and acyclovir was administered at 10 mg / kg / day dose, white skin fiol was 5 mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Login to view more

Abstract

The invention provides an application of piceatannol in preparation of a medicine for preventing and/or treating herpes simplex virus infection. Experiments prove that piceatannol has an inhibitory activity effect on herpes simplex virus infection, and the piceatannol has anti-HSV-1 and HSV-2 activity and is extremely low in toxicity. After piceatannol treatment, virus protein expression of HSV-1 and HSV-2 can be significantly inhibited, and obvious dose dependence is presented. The piceatannol achieves the effect of resisting herpes simplex virus infection by directly inactivating virus particles or intervening a replication process after a virus enters cells, so that virus proliferation is inhibited, the virus load in animal mouse tissues is reduced, the physical condition of a mouse is improved, and the body index of the mouse is increased, and therefore, the piceatannol has the potential of being prepared into the medicine for preventing and/or treating the herpes simplex virus.

Description

Technical field [0001] The present invention belongs to the field of medicine, particularly in applications involving piceatannol the prevention and / or medicament for the treatment of herpes simplex virus infections. Background technique [0002] Herpes virus is a double-stranded DNA enveloped viruses, the most typical herpes simplex virus (herpes simplexvirus, HSV) virus belongs to the Herpesviridae α subfamily, which according to the difference in antigenicity envelope glycoprotein can be divided into HSV-1 HSV-2 and two serotypes. HSV via the respiratory tract, the mouth, eye and genital mucosa and broken skin into the body, resulting in oral mucositis, encephalitis, keratoconjunctivitis and genital herpes disease. Wherein the primary HSV-2 infection caused by genital skin and mucous membranes, and the main cause of HSV-1 infection of the skin, mucous membranes and other than genital organs. To date, commonly used in clinical therapy mainly target the viral DNA polymerase an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/05A61P31/22
CPCA61K31/05A61P31/22
Inventor 郝翠王伟闫涵姚如永
Owner THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products